期刊文献+

卵巢囊肿恶性风险指数Ⅰ在卵巢囊肿良恶性评估中的应用价值 被引量:3

下载PDF
导出
摘要 目的探讨卵巢囊肿恶性风险指数I(RMI I)对恶性卵巢囊肿的诊断价值。方法对1101例具有病理诊断的患有卵巢囊肿的妇女进行回顾性研究,收集患者的人口学特点、CA125水平、超声特征,分别计算超声分数、CA125水平、绝经状态以及RMI I在评估附件包块良恶性时的敏感性、特异性、阳性预测值和阴性预测值。结果在鉴别妇女卵巢囊肿良恶性时,超声分数≥2的敏感性为80.4%,特异性为90.6%,阳性预测值为54%,阴性预测值为97%;CA125取临界值35U/m L,其敏感性、特异性、阳性预测值及阴性预测值分别是88%、76%、26.8%、97.6%,绝经后的敏感性、特异性、阳性预测值及阴性预测值分别是70.7%、86.5%、42.3%、95.6%。RMI I值的受试者工作曲线下面积(AUC)为0.948,诊断恶性卵巢囊肿价值最高,当临界值取200时的敏感性约91.7%,特异性95.6%,阳性预测值为73.9%,阴性预测值为98.8%。结论 RMI I较其他三种筛查方法独立判断卵巢囊肿恶性程度时有高的敏感性及特异性,在评估妇女卵巢囊肿恶性程度时,RMI I的最佳取值为200,这方法简单,可靠性高,易操作,适用于基层医院。
出处 《四川医学》 CAS 2017年第10期1147-1150,共4页 Sichuan Medical Journal
基金 宜宾市"一抓一"科技工程项目(编号:2012ZSF004)
  • 相关文献

参考文献2

二级参考文献17

  • 1Han L Y,Karavasilis V,Hagen T,et al.Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy[J].Eur J Cancer,2010,46(8):1359-1364.
  • 2Kang W D,Choi H S,Kim S M.Value of serum CA125 levels in patients with high-risk,early stage epithelial ovarian cancer[J].Gynecol Oncol,2010,116(1):57-60.
  • 3Ohel I,Sheiner E,Aricha-Tamir B,et al.Three-dimensional power Doppler ultrasound in ovarian cancer and its correlation with histology[J].Arch Gynecol Obstet,2010,281 (5):919-925.
  • 4Moolthiya W,Yuenyao P.The risk of malignancy index (RMI) in diagnosis of ovarian malignancy[J].Asian Pac J Cancer Prev,2009,10(5):865-868.
  • 5Tingulstad S,Hagen B,Skjeldestad FE,et al.The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals[J].Obstet Gynecol,1999,93(3):448-452.
  • 6Pepe M,Longton C,Janes H.Estimation and Comparison of Receiver Operating Characteristic Curves[J].Stata J,2009,9 (1):1.
  • 7Park S H,Goo J M,Jo C H.Receiver operating characteristic (ROC) curve:practical review for radiologists[J].Korean J Radiol,2004,5(1):11-18.
  • 8Matsuo K, Ahn EH, Prather CP, Eno ML, Im DD, Rosenshein NB. Patient-reported symptoms and survival in ovarian cancer. Int J Gynecol Cancer, 2011, 21 (9) : 1555-1565.
  • 9Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Com- parison of four malignancy risk indices in the preoperative evalua- tion of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol, 2009, 144 (2): 163-167.
  • 10Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dre- scher CW, Paley P, Urban N. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol, 2010, ii6 (3) : 378-383.

共引文献11

同被引文献25

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部